Mukoviszidose: Management im Zeitalter der CFTR-Modulator-Therapie

Die Mukoviszidose ist eine genetisch bedingte Systemerkrankung der exokrinen Drüsen, die lange Zeit zu einer reduzierten Lebenserwartung der betroffenen Patienten geführt hat. Der klinische Erfolg der Triple-Kombinationstherapie mit CFTR-Modulatoren Elexacaftor, Tezacaftor und Ivacaftor hat zu einem Paradigmenwechsel in Diagnostik, Therapie und Management geführt. Dieser Beitrag beleuchtet aktuelle Entwicklungen im Management der Mukoviszidose.

Schlüsselwörter

CFTR - CFTR-Modulator - Elexacaftor - Ivacaftor - Lumacaftor - Mukoviszidose - Tezacaftor

• Literatur

• 1 Shteinberg M, Haq IJ, Polineni D. et al. Cystic fibrosis. Lancet 2021; 397: 2195-2211
• 2 Mutation-specific Therapies in Cystic Fibrosis. Tümmler B. 2. Bremen: UNI-MED; 2022
• 3 Tümmler B. Mukoviszidose. Pädiatrie up2date 2018; 13: 43-65
• 4 CF-Manual. Ballmann M, Smaczny C, Sutharsan S, Dittrich A-M. 3rd. Stuttgart: Thieme; 2022
• 5 Tümmler B. Mukoviszidose: Genetik, Diagnostik und CFTR-Modulatoren. Pädiatrie up2date 2023; 18: 277-294
• 6 Higgins M, Volkova N, Moy K. et al. Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience. Pulm Ther 2020; 6: 141-149
• 7 Mayer-Hamblett N, Ratjen F, Russell R. et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med 2023; 11: 329-340
• 8 Graeber SY, Vitzthum C, Pallenberg ST. et al. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. Am J Respir Crit Care Med 2022; 205: 540-549
• 9 Pallenberg ST, Junge S, Ringshausen FC. et al. CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the β-adrenergic sweat rate assay. J Cyst Fibros 2022; 21: 442-447
• 10 Stanke F, Pallenberg ST, Tamm S. et al. Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy. Front Pharmacol 2023; 14: 1114584
• 11 Ringshausen FC, Sauer-Heilborn A, Büttner T. et al. Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012–2021. Eur Respir J 2023; 61: 2201402
• 12 Tümmler B. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor. Front Pharmacol 2023; 14: 1158207
• 13 Rowbotham NJ, Smith S, Elliott ZC. et al. A refresh of the top 10 research priorities in cystic fibrosis. Thorax 2023; 78: 840-843
• 14 Graeber SY, Renz DM, Stahl M. et al. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles. Am J Respir Crit Care Med 2022; 206: 311-320
• 15 Pallenberg ST, Pust MM, Rosenboom I. et al. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome. Microbiol Spectr 2022; 10: e0145422
• 16 Sun X, Yi Y, Yan Z. et al. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci Transl Med 2019; 11: eaau7531
• 17 Montemayor K, Tullis E, Jain R. et al. Management of pregnancy in cystic fibrosis. Breathe (Sheff) 2022; 18: 220005
• 18 Hong E, Almond LM, Chung PS. et al. Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria. Antimicrob Agents Chemother 2022; 66: e0110422
• 19 Mehta Z, Kamal KM, Miller R. et al. Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database. J Drug Assess 2021; 10: 62-67